CCDC43 Inhibitors
CCDC43 inhibitors compounds like cycloheximide and rapamycin are known to reduce overall protein synthesis, which could result in a decrease in CCDC43 protein levels. Inhibitors such as brefeldin A, monensin, and nocodazole disrupt intracellular transportation pathways, potentially affecting the trafficking and localization of CCDC43 within the cell.
Other molecules, including MG132 and chloroquine, can influence protein stability and degradation pathways, which may alter the turnover rate of CCDC43. Agents such as U18666A and mevastatin disrupt cholesterol metabolism and transport, potentially impacting cellular compartments and membrane microdomains where CCDC43 could be situated or required for proper function. Furthermore, compounds like 2-deoxy-D-glucose and tunicamycin interfere with fundamental processes such as glycolysis and protein glycosylation, respectively. If CCDC43 relies on glycosylation for its stability or activity, tunicamycin could have an impact on its function. Additionally, thapsigargin, by affecting calcium homeostasis, could influence signaling pathways or cellular events that involve CCDC43.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits protein synthesis by interfering with the translocation step in protein elongation, which could indirectly reduce CCDC43 levels. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts protein transport by inhibiting the exchange of protein ADP-ribosylation factor, potentially affecting CCDC43 trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
A carboxylic ionophore that disrupts intracellular protein transport by altering pH, possibly affecting CCDC43 localization. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can lead to reduced protein synthesis and could lower the expression levels of proteins like CCDC43. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can increase the levels of proteins targeted for degradation, potentially affecting CCDC43 stability. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Raises intracellular vesicle pH, which can disrupt endosomal trafficking and processes that CCDC43 might be part of. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $143.00 $510.00 | 2 | |
Inhibits intracellular cholesterol transport, which could affect membrane domains where CCDC43 is localized or functional. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
A glucose analog that inhibits glycolysis, potentially affecting cellular energy states and pathways involving CCDC43. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Blocks N-linked glycosylation, potentially disrupting protein folding and stability, affecting CCDC43 if it is glycosylated. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), potentially affecting calcium homeostasis related to CCDC43 function. | ||||||